x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001133
| Product Information | |
|---|---|
| Product Name | Human IGFBP3 ELISA Kit |
| Species | Human |
| Description | Human IGFBP3 ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of IGFBP3 protein in cell culture supernatant, plasma, and serum. It uses our proprietary ELISA technology. Quantitate Human IGFBP3 with 86.6 pg/mL sensitivity ELISA technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our ELISA plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. |
| Sample Types | Cell Culture Supernatant, Serum, Plasma |
| Detection Range | 122 pg/mL - 7800 pg/mL |
| Sensitivity | 86.6 pg/mL |
| Target Information | |
|---|---|
| Target Name | IGFBP3 |
| UniProt No. | P17936 |
| Gene ID | 3486 |
| Target Description | IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. |
| Alternative Names | Acid stable subunit of the 140 K IGF complex; Binding protein 29; Binding protein 53; BP 53; BP53; Growth hormone dependent binding protein; IBP 3; IBP-3; IBP3; IBP3_HUMAN; IGF binding protein 3; IGF-binding protein 3; IGFBP 3; IGFBP-3; IGFBP3; Insulin Like Growth Factor Binding Protein 3; Insulin-like growth factor binding protein 3 precursor; Insulin-like growth factor-binding protein 3 |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
